Expression of MACC1 and c-Met in human gastric cancer and its clinical significance

Cancer Cell International

Yaoxing Duan¹  Mingxu Da³  Yongbin Zhang¹  Jibin Yao³  Jingyu Yang²  Tiankang Guo³ 

[1] Department of Surgery, Ningxia Medical University, Yinchuan 750004, PR, China;Shandong Institute of Parasitic Diseases, Jining 272033, PR, China;Department of Surgical Oncology, Gansu Provincial Hospital, Lanzhou, 730000, PR, China

关键词: Hepatic metastasis;    Lymph node metastasis;    Peritoneal metastasis;    c-Met;    Metastasis associated with colon cancer1;    Gastric cancer;   

Others  :  792545
DOI  :  10.1186/1475-2867-13-121

 received in 2013-05-10, accepted in 2013-11-24,  发布年份 2013

【 摘 要 】

Background

Recent studies have suggested that the metastasis-associated colon cancer1 (MACC1) gene can promote tumor proliferation, invasion and metastasis through an upregulation of c-Met expression. However, its role in gastric cancer is controversial. Our study investigated expression of MACC1 and c-Met in gastric cancer, as well as correlated this with clinicopathological parameters.

Methods

Expressions of MACC1 and c-Met protein in a sample of 98 gastric carcinoma and adjacent nontumorous tissues were detected by immunohistochemistry. Their relationships and correlations with clinicopathological features were analyzed.

Results

The positive rates of MACC1 and c-Met protein in primary tumors were 61.22% and 59.18%, respectively. A significant correlation was found between expression of MACC1 and c-Met (P<0.05). Expression of the MACC1 protein in gastric cancer tissue was correlated with lymph node metastasis (χ² = 10.555,P = 0.001), peritoneal metastasis (χ² = 5.694, P = 0.017), and hepatic metastasis (χ² = 4.540,P = 0.033), but not with age, gender, tumor size, location, clinical stage or the distant metastases (P>0.05).

Conclusion

The positive rate of MACC1 protein expression was related to the protein expression of c-Met. Both had a correlation with the presence of peritoneal metastasis, lymph node metastasis and hepatic metastasis, all of which contribute to a poor prognosis for gastric cancer patients.

【 授权许可】

   
2013 Guo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Tavares A, Gandra A, Viveiros F, Cidade C, Maciel J: Analysis of clinicopathologic characteristics and prognosis of gastric cancer in young and older patients. Pathol Oncol Res 2013, 19:111-117.
• [2]Lin YS, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, Inoue M: Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 2011, 17:4421-4428.
• [3]Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009, 15:59-67.
• [4]Da MX, Wu Z, Tian HW: Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008, 39:365-372.
• [5]Zhou HY, Pon YL, Wong AS: HGF/MET signaling in ovarian cancer. Curr Mol Med 2008, 8:469-480.
• [6]Ogunwobi OO, Liu C: Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 2011, 28(8):721-731.
• [7]Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, Atabey N: HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res 2012, 18(2):209-218.
• [8]Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, Hwang HS, Choi EC: c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck 2010, 32:1655-1664.
• [9]Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H, Matsumoto Y: c-Met expression in gastric cancer with liver metastasis. Oncology 2002, 63:286-296.
• [10]Zhang W, Chu Y-Q, Ye Z-Y, Zhao Z-S, Tao H-Q: Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer. Anat Rec 2009, 292:1114-1121.
• [11]Amemiya H, Menolascino F, Pena A: Role of the expression of c-Met receptor in the progression of gastric cancer. Invest Clin 2010, 51:369-380.
• [12]Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, Yasumoto K: Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 2011, 141:895-898.
• [13]Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, Oyama T, Tanaka F: Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 2011, 31:1141-1145.
• [14]Gu C, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, Oyama T, Tanaka F: Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 2011, 31:1141-1145.
• [15]Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, et al.: MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res 2011, 31:777-780.
• [16]Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y: Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med 2011, 9:166. BioMed Central Full Text
• [17]Huang HL, Shi HR, Zhang RT, Chen ZM, Liu HN, Yuan ZF: Expression of MACC1 in epithelial ovarian cancer and its clinical significance. Tumor 2011, 31:522-526.
• [18]Zhang R, Shi H, Chen Z, Wu Q, Ren F, Huang H: Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res 2011, 30:83. BioMed Central Full Text
• [19]Boardman LA: Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med 2009, 1:36. BioMed Central Full Text
• [20]Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH: Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol 2012, 106(3):304-310.
• [21]Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M: Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005, 24:2885-2895.
• [22]Zhang QH, Qian K, Li XJ, Pu J, Wu XT: Experimental study of the hepatocyte growth factor contributing to lymphangiogenesis and lymphatic metastasis in gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2007, 10:212-216.
• [23]Glockzin G, Piso P: Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am 2012, 21:625-633.
• [24]Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, et al.: MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 2010, 30:3441-3444.
• [25]Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M: Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 2012, 130:2912-2921.
• [26]van Denderen BJ, Thompson EW: Cancer: the to and fro of tumour spread. Nature 2013, 493:487-488.
• [27]Theveneau E, Mayor R: Collective cell migration of epithelial and mesenchymal cells. Cell Mol Life Sci 2013, 70(19):3481-3492.
• [28]Jerraya H, Saidani A, Khalfallah M, Bouasker I, Nouira R, Dziri C: Management of liver metastases from gastric carcinoma: where is the evidence? Tunis Med 2013, 91:1-5.
• [29]Kodera Y: Treatment strategy for liver metastasis from gastric cancer. Nihon Geka Gakkai Zasshi 2012, 113:22-25.
• [30]Ge SH, Wu XJ, Wang XH, Xing XF, Zhang LH, Zhu YB, Du H, Dong B, Hu Y, Ji JF: Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients. Chin J Canc Res 2011, 23:153-159.
• [31]Stein U, Smith J, Walther W, Arlt F: MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle 2009, 8:2467-2469.